JP Morgan Private Wealth Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,247	Closed	-$226K	–	2054
2021 Q3	$226K	Sell	2,247 -21	-0.9%	-$2.46K	﹤0.01%	1810
2021 Q2	$321K	Sell	2,268 -107	-5%	-$12.1K	﹤0.01%	1651
2021 Q1	$237K	Sell	2,375 -43	-2%	-$5.01K	﹤0.01%	1621
2020 Q4	$299K	Sell	2,418 -1,134	-32%	-$149K	﹤0.01%	1499
2020 Q3	$346K	Buy	3,552 +618	+21%	+$77.2K	﹤0.01%	1300
2020 Q2	$458K	Buy	2,934 +747	+34%	+$114K	﹤0.01%	1141
2020 Q1	$316K	Buy	2,187 +338	+18%	+$65.3K	﹤0.01%	1115
2019 Q4	$378K	Buy	+1,849	New	+$337K	﹤0.01%	1145

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

JP Morgan Private Wealth Advisors's RETA Position: Q4 2021 in Review

JP Morgan Private Wealth Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 2,247 shares — an estimated $226K sold.

JP Morgan Private Wealth Advisors first reported a position in RETA in Q4 2019 and held it in 8 quarters. The position peaked at $458K in Q2 2020. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.

JP Morgan Private Wealth Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
JP Morgan Private Wealth Advisors sold 2,247 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $226K.
JP Morgan Private Wealth Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 8 quarters.
JP Morgan Private Wealth Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $458K in Q2 2020.
151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.